Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T‐cell lymphoma

Abstract

Pralatrexate is a novel antifolate approved in the USA for the treatment of relapsed or refractory peripheral T-cell lymphoma. To assess its safety, efficacy, and pharmacokinetics in Japanese patients with this disease, we undertook a phase I/II study. Pralatrexate was given i.v. weekly for 6 weeks of a 7-week cycle. All patients received concurrent vitamin… (More)
DOI: 10.1111/cas.13340

Topics

Cite this paper

@inproceedings{Maruyama2017PhaseIS, title={Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T‐cell lymphoma}, author={Dai Maruyama and Hirokazu Nagai and Yoshinobu Maeda and Takahiko Nakane and Tatsu Shimoyama and Tomonori Nakazato and Rika Sakai and Takayuki Ishikawa and K. T. Izutsu and Ryuzo Ueda and Kensei Tobinai}, booktitle={Cancer science}, year={2017} }